What's Happening?
The U.S. Food and Drug Administration (FDA) has approved POHERDY (pertuzumab-dpzb), the first biosimilar to PERJETA (pertuzumab) for HER2-positive breast cancer. Developed by Shanghai Henlius Biotech and Organon,
POHERDY is intended for use in combination with trastuzumab and docetaxel for treating adults with HER2-positive metastatic breast cancer. This approval marks a significant milestone in expanding access to affordable biologic therapies for cancer patients. The biosimilar is expected to provide a cost-effective alternative to the reference product, potentially reducing healthcare costs.
Why It's Important?
The approval of POHERDY represents a critical step in increasing the availability of affordable cancer treatments in the U.S. Biosimilars offer a cost-effective alternative to expensive biologic drugs, potentially reducing the financial burden on patients and the healthcare system. This development could encourage further investment in biosimilar research and development, leading to more treatment options for patients. The collaboration between Henlius and Organon highlights the importance of international partnerships in advancing healthcare innovation and accessibility.
